|
1
|
Padala SA and Barsouk A, Thandra KC,
Saginala K, Mohammed A, Vakiti A, Rawla P and Barsouk A:
Epidemiology of renal cell carcinoma. World J Oncol. 11:79–87.
2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Srigley JR, Amin MB, Delahunt B, Campbell
SC, Chang A, Grignon DJ, Humphrey PA, Leibovich BC, Montironi R,
Renshaw AA, et al: Protocol for the examination of specimens from
patients with invasive carcinoma of renal tubular origin. Arch
Pathol Lab Med. 134:e25–e30. 2010.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Moch H, Cubilla AL, Humphrey PA, Reuter VE
and Ulbright TM: The 2016 WHO classification of tumours of the
urinary system and male genital organs-part A: Renal, penile, and
testicular tumours. Eur Urol. 70:93–105. 2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Motzer RJ, Jonasch E, Agarwal N, Bhayani
S, Bro WP, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Fishman
M, et al: Kidney cancer, version 2.2017, NCCN clinical practice
guidelines in oncology. J Natl Compr Canc Netw. 15:804–834.
2017.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Warren AY and Harrison D: WHO/ISUP
classification, grading and pathological staging of renal cell
carcinoma: Standards and controversies. World J Urol. 36:1913–1926.
2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Leibovich BC, Lohse CM, Crispen PL,
Boorjian SA, Thompson RH, Blute ML and Cheville JC: Histological
subtype is an independent predictor of outcome for patients with
renal cell carcinoma. J Urol. 183:1309–1315. 2010.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Nickerson ML, Jaeger E, Shi Y, Durocher
JA, Mahurkar S, Zaridze D, Matveev V, Janout V, Kollarova H, Bencko
V, et al: Improved identification of von Hippel-Lindau gene
alterations in clear cell renal tumors. Clin Cancer Res.
14:4726–4734. 2008.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Sadri N and Zhang PJ: Hypoxia-inducible
factors: Mediators of cancer progression; prognostic and
therapeutic targets in soft tissue sarcomas. Cancers (Basel).
5:320–333. 2013.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Keith B, Johnson RS and Simon MC: HIF1α
and HIF2α: Sibling rivalry in hypoxic tumour growth and
progression. Nat Rev Cancer. 12:9–22. 2011.PubMed/NCBI View
Article : Google Scholar
|
|
11
|
Semenza GL: Hypoxia-inducible factors:
Mediators of cancer progression and targets for cancer therapy.
Trends Pharmacol Sci. 33:207–214. 2012.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Mueckler M and Thorens B: The SLC2 (GLUT)
family of membrane transporters. Mol Aspects Med. 34:121–138.
2013.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Barron CC, Bilan PJ, Tsakiridis T and
Tsiani E: Facilitative glucose transporters: Implications for
cancer detection, prognosis and treatment. Metabolism. 65:124–139.
2016.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Hatanaka M: Transport of sugars in tumor
cell membranes. Biochim Biophys Acta. 355:77–104. 1974.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Navale AM and Paranjape AN: Glucose
transporters: Physiological and pathological roles. Biophys Rev.
8:5–9. 2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Gu J, Yamamoto H, Fukunaga H, Danno K,
Takemasa I, Ikeda M, Tatsumi M, Sekimoto M, Hatazawa J, Nishimura T
and Monden M: Correlation of GLUT-1 overexpression, tumor size, and
depth of invasion with 18F-2-fluoro-2-deoxy-D-glucose uptake by
positron emission tomography in colorectal cancer. Dig Dis Sci.
51:2198–2205. 2006.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Kurokawa T, Yoshida Y, Kawahara K,
Tsuchida T, Okazawa H, Fujibayashi Y, Yonekura Y and Kotsuji F:
Expression of GLUT-1 glucose transfer, cellular proliferation
activity and grade of tumor correlate with
[F-18]-fluorodeoxyglucose uptake by positron emission tomography in
epithelial tumors of the ovary. Int J Cancer. 109:926–932.
2004.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Park SG, Lee JH, Lee WA and Han KM:
Biologic correlation between glucose transporters, hexokinase-II,
Ki-67 and FDG uptake in malignant melanoma. Nucl Med Biol.
39:1167–1172. 2012.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Sung JY, Kim GY, Lim SJ, Park YK and Kim
YW: Expression of the GLUT1 glucose transporter and p53 in
carcinomas of the pancreatobiliary tract. Pathol Res Pract.
206:24–29. 2010.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Haber RS, Rathan A, Weiser KR, Pritsker A,
Itzkowitz SH, Bodian C, Slater G, Weiss A and Burstein DE: GLUT1
glucose transporter expression in colorectal carcinoma: A marker
for poor prognosis. Cancer. 83:34–40. 1998.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Cantuaria G, Fagotti A, Ferrandina G,
Magalhaes A, Nadji M, Angioli R, Penalver M, Mancuso S and Scambia
G: GLUT-1 expression in ovarian carcinoma: Association with
survival and response to chemotherapy. Cancer. 92:1144–1150.
2001.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Hoskin PJ, Sibtain A, Daley FM and Wilson
GD: GLUT1 and CAIX as intrinsic markers of hypoxia in bladder
cancer: Relationship with vascularity and proliferation as
predictors of outcome of ARCON. Br J Cancer. 89:1290–1297.
2003.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Tohma T, Okazumi S, Makino H, Cho A,
Mochizuki R, Shuto K, Kudo H, Matsubara K, Gunji H, Matsubara H and
Ochiai T: Overexpression of glucose transporter 1 in esophageal
squamous cell carcinomas: A marker for poor prognosis. Dis
Esophagus. 18:185–189. 2005.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Yeluri S, Madhok B, Prasad KR, Quirke P
and Jayne DG: Cancer's craving for sugar: An opportunity for
clinical exploitation. J Cancer Res Clin Oncol. 135:867–877.
2009.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Hardie DG and Ashford ML: AMPK: Regulating
energy balance at the cellular and whole body levels. Physiology
(Bethesda). 29:99–107. 2014.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Melstrom LG, Salabat MR, Ding XZ, Milam
BM, Strouch M, Pelling JC and Bentrem DJ: Apigenin inhibits the
GLUT-1 glucose transporter and the phosphoinositide 3-kinase/Akt
pathway in human pancreatic cancer cells. Pancreas. 37:426–431.
2008.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Wood TE, Dalili S, Simpson CD, Hurren R,
Mao X, Saiz FS, Gronda M, Eberhard Y, Minden MD, Bilan PJ, et al: A
novel inhibitor of glucose uptake sensitizes cells to FAS-induced
cell death. Mol Cancer Ther. 7:3546–3555. 2008.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Zhang D, Wang Y, Dong L, Huang Y, Yuan J,
Ben W, Yang Y, Ning N, Lu M and Guan Y: Therapeutic role of EF24
targeting glucose transporter 1-mediated metabolism and metastasis
in ovarian cancer cells. Cancer Sci. 104:1690–1696. 2013.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Rastogi S, Banerjee S, Chellappan S and
Simon GR: Glut-1 antibodies induce growth arrest and apoptosis in
human cancer cell lines. Cancer Lett. 257:244–251. 2007.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Wang YD, Li SJ and Liao JX: Inhibition of
glucose transporter 1 (GLUT1) chemosensitized head and neck cancer
cells to cisplatin. Technol Cancer Res Treat. 12:525–535.
2013.PubMed/NCBI View Article : Google Scholar
|
|
31
|
World Medical Association: World medical
association declaration of Helsinki. Ethical principles for medical
research involving human subjects. JAMA. 310:2191–2194.
2013.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Tomas SZ, Prusac IK, Roje D and Tadin I:
Trophoblast apoptosis in placentas from pregnancies complicated by
preeclampsia. Gynecol Obstet Invest. 71:250–255. 2011.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Nagase Y, Takata K, Moriyama N, Aso Y,
Murakami T and Hirano H: Immunohistochemical localization of
glucose transporters in human renal cell carcinoma. J Urol.
153:798–801. 1995.PubMed/NCBI
|
|
34
|
Ambrosetti D, Dufies M, Dadone B, Durand
M, Borchiellini D, Amiel J, Pouyssegur J, Rioux-Leclercq N, Pages
G, Burel-Vandenbos F and Mazure NM: The two glycolytic markers
GLUT1 and MCT1 correlate with tumor grade and survival in
clear-cell renal cell carcinoma. PLoS One.
13(e0193477)2018.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Ozcan A, Shen SS, Zhai QJ and Truong LD:
Expression of GLUT1 in primary renal tumors: Morphologic and
biologic implications. Am J Clin Pathol. 128:245–254.
2007.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Kobayashi M, Uematsu T, Tokura Y, Takei K,
Sakamoto K, Narimatsu T, Nukui A and Kamai T: Immunohistochemical
expressionof sodium-dependent glucose transporter-2 (SGLT-2) in
clear cell renal carcinoma: Possible prognostic implications. Int
Braz J Urol. 45:169–178. 2019.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Lidgren A, Bergh A, Grankvist K, Rasmuson
T and Ljungberg B: Glucose transporter-1 expression in renal cell
carcinoma and its correlation with hypoxia inducible factor-1
alpha. BJU Int. 101:480–484. 2008.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Wang J, Ye C, Chen C, Xiong H, Xie B, Zhou
J, Chen Y, Zheng S and Wang L: Glucose transporter GLUT1 expression
and clinical outcome in solid tumors: A systematic review and
meta-analysis. Oncotarget. 8:16875–16886. 2017.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Singer K, Kastenberger M, Gottfried E,
Hammerschmied CG, Büttner M, Aigner M, Seliger B, Walter B,
Schlösser H, Hartmann A, et al: Warburg phenotype in renal cell
carcinoma: High expression of glucose-transporter 1 (GLUT-1)
correlates with low CD8(+) T-cell infiltration in the tumor. Int J
Cancer. 128:2085–2095. 2011.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Adekola K, Rosen ST and Shanmugam M:
Glucose transporters in cancer metabolism. Curr Opin Oncol.
24:650–654. 2012.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Page T, Hodgkinson AD, Ollerenshaw M,
Hammonds JC and Demaine AG: Glucose transporter polymorphisms are
associated with clear-cell renal carcinoma. Cancer Genet Cytogenet.
163:151–155. 2005.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Vera JC, Reyes AM, Velasquez FV, Rivas CI,
Zhang RH, Strobel P, Slebe JC, Núñez-Alarcón J and Golde DW: Direct
inhibition of the hexose transporter GLUT1 by tyrosine kinase
inhibitors. Biochemistry. 40:777–790. 2001.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Zambrano A, Molt M, Uribe E and Salas M:
Glut 1 in cancer cells and the inhibitory action of resveratrol as
a potential therapeutic strategy. Int J Mol.
20(3374)2019.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Chan DA, Sutphin PD, Nguyen P, Turcotte S,
Lai EW, Banh A, Reynolds GE, Chi JT, Wu J, Solow-Cordero DE, et al:
Targeting GLUT1 and the Warburg effect in renal cell carcinoma by
chemical synthetic lethality. Sci Transl Med.
3(94ra70)2011.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Shuch B, Linehan WM and Srinivasan R:
Aerobic glycolysis: A novel target in kidney cancer. Expert Rev
Anticancer Ther. 13:711–719. 2013.PubMed/NCBI View Article : Google Scholar
|
